High Activity 177Lu-PSMA Therapy Of Metastatic Castration-resistant Prostate Cancer

被引：0
|
作者：
Happel, C. [1 ]
Kranert, W. T. [1 ]
Bockisch, B. [1 ]
Groener, D. [1 ]
Davis, K. H. [1 ]
Wichert, J. [1 ]
Stefanova, M. [1 ]
Gruenwald, F. [1 ]
Sabet, A. [1 ]
机构：
[1] Univ Med Ctr Frankfurt, Dept Nucl Med, Frankfurt, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2019年 / 46卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP-0580
引用
收藏
页码：S647 / S648
页数：2
相关论文
共 50 条
  • [41] Intermittent Lu-177-PSMA-617 therapy of metastatic castration-resistant prostate cancer in early responders
    Mader, Nicolai
    Ngoc, Christina Nguyen
    Baumgarten, Justus
    Groener, Daniel
    Davis, Karen
    Wichert, Jennifer
    Tselis, Nikolaos
    Mandel, Philipp
    Gruenwald, Frank
    Sabet, Amir
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [42] Promising 177Lu-PSMA-617 Therapy Results in Patients with Metastatic Castration-Resistant Prostate Cancer
    Brnjic, Antonio
    Frye, Sarah
    Botkin, Crystal
    Osman, Medhat
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62
  • [43] 177Lu-PSMA-RLT of metastatic castration-resistant prostate cancer: limitations and improvements
    Jianpeng Cao
    Yue Chen
    Mei Hu
    Wei Zhang
    Annals of Nuclear Medicine, 2021, 35 : 861 - 870
  • [44] 177Lu-PSMA-RLT of metastatic castration-resistant prostate cancer: limitations and improvements
    Cao, Jianpeng
    Chen, Yue
    Hu, Mei
    Zhang, Wei
    ANNALS OF NUCLEAR MEDICINE, 2021, 35 (08) : 861 - 870
  • [45] [177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer
    Rahbar, Kambiz
    Ahmadzadehfar, Hojjat
    Seifert, Robert
    Boegemann, Martin
    LANCET ONCOLOGY, 2018, 19 (08): : E371 - E371
  • [46] Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
    Sun, Michael
    Niaz, Muhammad O.
    Nelson, Adlai
    Skafida, Myrto
    Niaz, Muhammad J.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (06)
  • [47] Extended therapy with Lu-177-PSMA-617 in patients with high tumor load metastatic castration-resistant prostate cancer
    Mader, Nicolai
    Baumgarten, Justus
    Groner, Daniel
    Ngoc, Christina Nguyen
    Davis, Karen
    Banek, Severine
    Tselis, Nikolaos
    Happel, Christian
    Gruenwald, Frank
    Sabet, Amir
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [48] Excellent Response to 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in a Patient With Progressive Metastatic Castration-Resistant Prostate Cancer With Neuroendocrine Differentiation After 177Lu-PSMA Therapy
    Liu, Chen
    Liu, Teli
    Zhang, Jingjing
    Baum, Richard P.
    Yang, Zhi
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (11) : 876 - 878
  • [49] Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer
    Bernhard Grubmüller
    Daniela Senn
    Gero Kramer
    Pascal Baltzer
    David D’Andrea
    Karl Hermann Grubmüller
    Markus Mitterhauser
    Harald Eidherr
    Alexander R. Haug
    Wolfgang Wadsak
    Sarah Pfaff
    Shahrokh F. Shariat
    Marcus Hacker
    Markus Hartenbach
    European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 1063 - 1072
  • [50] Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer
    Houede, Nadine
    Hebert, Kevin
    LANCET ONCOLOGY, 2024, 25 (05): : 531 - 533
12345